Lonza scores 18 per cent net profit on biopharma strategy
Swiss chemicals firm and contract manufacturer Lonza has announced 18 per cent rise in net profit in 2006 rising to CHF 222m (€137.4), fuelled by its strategic move into biopharmaceuticals.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs